Viracta Therapeutics 2024 Clinical Pipeline EBV+ Lymphoma

Viracta Therapeutics is developing antiviral-based immunotherapies targeting virus-associated malignancies, particularly EBV+ lymphoma and solid tumors. The presentation outlines the company's clinical development pipeline, including the NAVAL-1 trial, and leadership team expertise in viral oncology. Focus areas include nanatinostat and valganciclovir combination therapies with plans for FDA discussions and potential NDA filings.